Pharmion European Thalidomide Application For Multiple Myeloma Withdrawn; Resubmission Planned
This article was originally published in The Pink Sheet Daily
Executive Summary
Data from two ongoing trials are expected to fill out the resubmission. The withdrawal decision was not based on safety issues, Pharmion says.